Total Payments
$630,063
2023 Payments
$16,822
Companies
5
Transactions
15
Medicare Patients
2,953
Medicare Billing
$330,633
Payment Breakdown by Category
Research$629,913 (100.0%)
Food & Beverage$150.67 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $629,913 | 6 | 100.0% |
| Food and Beverage | $150.67 | 9 | 0.0% |
Payments by Type
Research
$629,913
6 transactions
General
$150.67
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $629,913 | 6 | $0 (2023) |
| AbbVie Inc. | $98.52 | 6 | $0 (2023) |
| Allergan Inc. | $23.82 | 1 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $14.44 | 1 | $0 (2021) |
| Alexion Pharmaceuticals, Inc. | $13.89 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $16,822 | 4 | Eli Lilly and Company ($16,791) |
| 2022 | $591,314 | 4 | Eli Lilly and Company ($591,281) |
| 2021 | $8,604 | 5 | Eli Lilly and Company ($8,541) |
| 2020 | $13,300 | 1 | Eli Lilly and Company ($13,300) |
| 2018 | $23.82 | 1 | Allergan Inc. ($23.82) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/11/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $12,166.00 | Research |
| Study: A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | ||||||
| 09/20/2023 | AbbVie Inc. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/31/2023 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $4,625.05 | Research |
| Study: A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | ||||||
| 11/29/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $573,630.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 09/06/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/09/2022 | ABBVIE INC. | DALVANCE (Drug), TEFLARO | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/08/2022 | Eli Lilly and Company | — | — | In-kind items and services | $17,651.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 11/16/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/14/2021 | Alexion Pharmaceuticals, Inc. | Andexxa (Drug) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Hematology | ||||||
| 08/04/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $11.12 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/05/2021 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/05/2021 | Eli Lilly and Company | — | — | In-kind items and services | $8,540.75 | Research |
| Study: A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 IN PREVENTING SARS COV 2 INFECTION AND COVID 19 IN SKILLED NURSING AND ASSISTED LIVING FACILITY RESIDENTS AND STAFF A NIAID AND LILLY COLLABORATIVE STUDY | ||||||
| 11/09/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $13,300.00 | Research |
| Study: A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 IN PREVENTING SARS COV 2 INFECTION AND COVID 19 IN SKILLED NURSING AND ASSISTED LIVING FACILITY RESIDENTS AND STAFF A NIAID AND LILLY COLLABORATIVE STUDY | ||||||
| 11/05/2018 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $23.82 | General |
| Category: ANTI-INFECTIVE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $591,281 | 2 |
| A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 IN PREVENTING SARS COV 2 INFECTION AND COVID 19 IN SKILLED NURSING AND ASSISTED LIVING FACILITY RESIDENTS AND STAFF A NIAID AND LILLY COLLABORATIVE STUDY | Eli Lilly and Company | $21,841 | 2 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $16,791 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 684 | 751 | $178,935 | $60,784 |
| 2022 | 10 | 618 | 660 | $184,386 | $63,267 |
| 2021 | 8 | 776 | 855 | $260,955 | $98,404 |
| 2020 | 8 | 875 | 970 | $319,717 | $108,179 |
Total Patients
2,953
Total Services
3,236
Medicare Billing
$330,633
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99285 | Emergency department visit with high level of medical decision making | Facility | 2023 | 179 | 197 | $64,419 | $24,716 | 38.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 80 | 88 | $44,440 | $13,345 | 30.0% |
| 99284 | Emergency department visit with moderate level of medical decision making | Facility | 2023 | 132 | 138 | $30,912 | $11,146 | 36.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 38 | $7,258 | $3,358 | 46.3% |
| 99283 | Emergency department visit with low level of medical decision making | Facility | 2023 | 61 | 62 | $7,378 | $2,998 | 40.6% |
| 31500 | Emergent insertion of breathing tube into windpipe using an endoscope | Facility | 2023 | 16 | 16 | $5,648 | $1,673 | 29.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $4,464 | $1,545 | 34.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 168 | 184 | $3,680 | $1,048 | 28.5% |
| 36556 | Insertion of non-tunneled central venous tube for infusion (5 years or older) | Facility | 2023 | 14 | 16 | $10,736 | $953.73 | 8.9% |
| 99285 | Emergency department visit for life threatening or functioning severity | Facility | 2022 | 178 | 190 | $62,130 | $24,899 | 40.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 86 | 94 | $47,470 | $14,911 | 31.4% |
| 99284 | Emergency department visit for problem of high severity | Facility | 2022 | 131 | 139 | $31,136 | $11,773 | 37.8% |
| 99283 | Emergency department visit for problem of moderate severity | Facility | 2022 | 101 | 105 | $12,495 | $5,060 | 40.5% |
| 92950 | Manual attempt to restore blood circulation and breathing | Facility | 2022 | 15 | 15 | $11,490 | $1,994 | 17.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 20 | $3,820 | $1,539 | 40.3% |
| 31500 | Emergent insertion of breathing tube into windpipe using an endoscope | Facility | 2022 | 15 | 15 | $5,295 | $1,519 | 28.7% |
| 36556 | Insertion of non-tunneled central venous tube for infusion (5 years or older) | Facility | 2022 | 12 | 12 | $8,052 | $712.75 | 8.9% |
| 99282 | Emergency department visit for problem of mild to moderate severity | Facility | 2022 | 18 | 18 | $1,458 | $531.43 | 36.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 51 | 52 | $1,040 | $326.56 | 31.4% |
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2021 | 333 | 389 | $127,203 | $53,905 | 42.4% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 100 | 102 | $51,510 | $17,549 | 34.1% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2021 | 106 | 107 | $23,968 | $9,986 | 41.7% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2021 | 149 | 166 | $19,754 | $8,885 | 45.0% |
| 31500 | Emergent insertion of breathing tube into windpipe cartilage using an endoscope | Facility | 2021 | 36 | 37 | $13,061 | $4,074 | 31.2% |
| 92950 | Attempt to restart heart and lungs | Facility | 2021 | 17 | 17 | $13,022 | $2,445 | 18.8% |
About Dr. Jason Begue, MD
Dr. Jason Begue, MD is a Emergency Medicine healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/11/2005. The National Provider Identifier (NPI) number assigned to this provider is 1336120682.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jason Begue, MD has received a total of $630,063 in payments from pharmaceutical and medical device companies, with $16,822 received in 2023. These payments were reported across 15 transactions from 5 companies. The most common payment nature is "" ($629,913).
As a Medicare-enrolled provider, Begue has provided services to 2,953 Medicare beneficiaries, totaling 3,236 services with total Medicare billing of $330,633. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Emergency Medicine
- Location Birmingham, AL
- Active Since 11/11/2005
- Last Updated 12/15/2009
- Taxonomy Code 207P00000X
- Entity Type Individual
- NPI Number 1336120682
Products in Payments
- DALVANCE (Drug) $54.55
- TEFLARO (Drug) $40.23
- AVYCAZ (Drug) $27.56
- LOKELMA (Drug) $14.44
- Andexxa (Drug) $13.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Emergency Medicine Doctors in Birmingham
Dr. James Galbraith, Md, MD
Emergency Medicine — Payments: $98,909
Emergency Medicine $98,909
Lauren Walter
Emergency Medicine — Payments: $64,781
Emergency Medicine $64,781
Suresh Boppana, Md, MD
Emergency Medicine — Payments: $54,221
Emergency Medicine $54,221
Dr. Thomas Atkinson, Md, MD
Emergency Medicine — Payments: $47,171
Emergency Medicine $47,171
Cornelius Meadows, M.d, M.D
Emergency Medicine — Payments: $12,606
Emergency Medicine $12,606
Jimmie Dotson, M.d, M.D
Emergency Medicine — Payments: $12,563
Emergency Medicine $12,563